Abstract
Background: For cannabis-dependent subjects, the relationship between cannabis withdrawal syndrome (CWS) severity and the urine cannabinoid concentrations are unclear; we investigated this using a commercial point-of-care (POC) enzyme immunoassay detecting 11-nor-9-carboxy-Delta-9-tetrahydrocannabinol (THC-COOH).Methods: Observational study of 78 adult chronic cannabis-dependent subjects assessed over a 24-day inpatient detoxification treatment, with 13 serial measurement days. Repeated Measures Correlation and Multilevel Linear Models were employed.Results: Absolute urinary THC-COOH levels significantly correlated with Marijuana Withdrawal Checklist (MWC) scores across the entire study duration (r = 0.248; p < 0.001). Correlation between serial creatinine-adjusted THC-COOH ratios and serial MWC scores emerged as significant only in the sample with higher MWC scores (>11 points) at admission (n = 21; r = 0.247; p = 0.002). The aforementioned significant relationships have persisted when replacing the absolute THC-COOH-levels with the (relative) day-to-day change in urinary THC-COOH levels. MWC scores were significantly correlated with the Clinical Global Impression-Severity (CGI-S; r = 0.812; p < 0.001). Females showed a significantly slower decline in urine THC-COOH levels and prolonged CWS course characterized by substantial illness severity (per CGI-S), occurring in nearly 30% of cases.Conclusion: Urine cannabinoid levels (THC-COOH) determined by POC assay significantly predicted CWS severity (moderate correlation), guiding detoxification treatment duration. In patients with MWC > 11 points upon admission, creatinine-adjusted THC-COOH ratios also significantly predicted CWS severity—again with moderate effect size. Females showed prolonged urinary THC-COOH elimination and cannabis withdrawal.
Highlights
The abrupt cessation of frequent cannabis intake is followed by a cannabis withdrawal syndrome (CWS), primarily presenting with emotional and behavioral symptoms [1,2,3]
We investigated the correlation between the clinical CWS course of cannabis-dependent persons seeking inpatient detoxification treatment and the trends of their urine cannabinoid levels as measured by the semiquantitative DRI R Cannabinoid Assay [15]
To the best of our knowledge, this study is the first to demonstrate the significant association between urine THC-COOH levels and CWS severity, which proved to be a robust finding via regression analyses, rmcorr and Multilevel Linear Models (MLM)
Summary
The abrupt cessation of frequent cannabis intake is followed by a cannabis withdrawal syndrome (CWS), primarily presenting with emotional and behavioral symptoms [1,2,3]. CWS is a key component of the cannabis dependence syndrome (CDS) as defined in ICD-10, with nearly 90% of these individuals displaying clinically relevant CWS [5]. Discontinuation of synthetic cannabinoids (which are generally full CB1 agonists) [6] leads to a similar withdrawal syndrome [3]; CB1 agonists alleviate CWS symptoms [3, 7]. For cannabis-dependent subjects, the relationship between cannabis withdrawal syndrome (CWS) severity and the urine cannabinoid concentrations are unclear; we investigated this using a commercial point-of-care (POC) enzyme immunoassay detecting 11-nor-9-carboxy-Delta-9-tetrahydrocannabinol (THC-COOH)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.